Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GSK Strategic Moves in U.K. to Result in New Investments, Possible Plant Closure, Some Job Losses

By GlaxoSmithKline plc | July 20, 2017

GSK updates on U.K. manufacturing network.

GSK this week issued several announcements intended to improve the efficiency and competitiveness of its manufacturing network. These include both investments for respiratory and HIV medicines manufacturing in the U.K. and strategic reviews, including the sale of several products and a proposal to close a U.K. manufacturing site.

Between now and 2020, the company plans to invest more than £140 million ($182 million) at its Ware, Hertfordshire, Barnard Castle, Co Durham and Montrose, Scotland sites. The investments will support expansion of manufacturing for respiratory and HIV medicines. This new investment is in addition to the £275 million ($357 million) announced last year and investment of over £1.2 billion ($1.6 billion) in U.K. manufacturing since 2012.

(Editor’s Note: Exchange rates calculated at £1 = $1.30 on July 20, 2017)

In pharmaceuticals, the company is to undertake a strategic review of its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities. These medicines are produced at GSK sites in Ulverston, Cumbria, Verona in Italy and part of its Barnard Castle site. The company has also decided to outsource some manufacturing activity at its Worthing site in the U.K.

GSK will continue to manufacture other antibiotics such as Augmentin and will continue to conduct research on new antibiotics. The company has also decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity.

In its Consumer Healthcare business, the company intends to sell its Horlicks brand in the U.K. and is proposing to close the associated manufacturing site in Slough where U.K. product is made. In addition, GSK intends to sell the MaxiNutrition brand in the U.K.  GSK is also exploring options to divest some other smaller non-core nutrition brands.

Overall, GSK employs a total of around 17,000 people across the U.K. of which 5,000 are in U.K. manufacturing operations. The proposals announced today for Worthing and Slough will result in a reduction of approximately 320 permanent jobs over the next 4 years.

Roger Connor, president, GSK Global Manufacturing and Supply said: “We have a substantial manufacturing presence in the U.K. and continue to support the network with new investment of more than £140 million in the next 3 years. At the same time, we have had to make some decisions which we know will cause uncertainty for some of our employees. We will do all we can to support them through this process.”

Philip Thomson, president, Global Affairs, GSK, said: “We are continuing to invest in science and our core businesses in the U.K. and we continue to see the U.K. as an attractive place for the life sciences industry. We are working constructively with the government and others to develop an ambitious plan for the sector as part of the U.K.’s new industrial strategy.”

The company said that none of the announcements made this week by GSK have resulted from the U.K.’s decision to leave the European Union.

(Source: GlaxoSmithKline plc)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE